Ameriprise
CADX

Ameriprise’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Ameriprise’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-160
Closed -$1K – 5530
2013
Q4 		$1K Sell
160
-4,095
-96% -$29.6K ﹤0.01% 5076
2013
Q3 		$27K Hold
4,255
– – ﹤0.01% 4222
2013
Q2 		$29K Buy
+4,255
New +$29.6K ﹤0.01% 4066

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ameriprise's CADX Position: Q1 2014 in Review

Ameriprise sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 160 shares — an estimated $1K sold.

Ameriprise first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $29K in Q2 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • Ameriprise reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • Ameriprise sold 160 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $1K.
  • Ameriprise first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
  • Ameriprise's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $29K in Q2 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Ameriprise's 13F filing for Q1 2014, filed 14 May 2014.